The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.
Drug repurposing: a promising tool to accelerate the drug discovery process
Open accessAbstract
Traditional drug discovery and development involves several stages for the discovery of a new drug and to obtain marketing approval. It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. Typically, repurposing can be achieved serendipitously (unintentional fortunate observations) or through systematic approaches. Numerous strategies to discover new indications for FDA-approved drugs are discussed in this article. Drug repurposing has therefore become a productive approach for drug discovery because it provides a novel way to explore old drugs for new use but encounters several challenges. Some examples of different approaches are reviewed here.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These tools can identify ligands, decode drug ingredient binding schemas, and highlight promising candidates from an expansive list of potential compounds.27,31,32”
From Drug repurposing for cancer therapy (2024) · cites this paper as [27]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 996
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 498
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438
Flagged first, then by citations
2 of the 87 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Repurposing drugs helps patients with rare diseases. Available at: https://www.elsevier.com/connect/repurposing-drugs-helps-patients-with-rare-diseases.
- Sekhon, 2013, Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications, J. Pharm. Educ. Res., 4, 1
Cited by
Sorted by citations
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y. F., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 499
“It refers to a method that identi fi es new indications for approved drugs or drug candidates which have failed in the development phase 232 .”
MethodDrug repurposing for cancer therapy
Xia, Y., Sun, M., Huang, H., & Jin, W.-L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01808-1 · Cited by 443
“27,28 More often, these techniques are synergistically utilized.”
BackgroundMethodDrug Repurposing: An Effective Tool in Modern Drug Discovery
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020139 · Cited by 264
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140
“This means the success rate of drug approval is so high when compared to the traditional methods [202].”
ResultUtilizing drug repurposing against COVID-19 – Efficacy, limitations, and challenges
Parvathaneni, V., & Gupta, V. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118275 · Cited by 138
“Apart from serendipitous observations, drug repurposing can be executed through several strategies including binding assays and phenotypic screening methods or computational methods, as presented in Table 1 [23].”
InfluentialSelf-citationTargeted inhibition of tumor-derived exosomes as a novel therapeutic option for cancer
Li, Y., Chen, Z.-K., Duan, X., Zhang, H., Xiao, B.-L., Wang, K.-M., & Chen, G. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00856-3 · Cited by 114
The Role of AI in Drug Discovery
Abbas, M. K. G., Rassam, A., Karamshahi, F., Abunora, R., & Abouseada, M. (2024) · ChemBioChem · doi:10.1002/cbic.202300816 · Cited by 119
Computational drug repurposing: approaches, evaluation of in silico resources and case studies
Tanoli, Z., Fernández‐Torras, A., Özcan, U. O., Kushnir, A., Nader, K. M., Gadiya, Y., Fiorenza, L., Ianevski, A., Vähä-Koskela, M. J. V., Miihkinen, M., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01164-x · Cited by 104
“Furthermore, the safety and toxicity profiles established for the original indication may not be predictive when the drug is used in a new context, especially with chronic or high-dose regimens 203 .”
Liu, L.-X., Heng, J.-H., Deng, D.-X., Zhao, H., Zheng, Z.-Y., Liao, L., Lin, W., Xu, X., Li, E., & Xu, L. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100551 · Cited by 91
“Drug repositioning, the new use of old clinically approved drugs, can save time and cost with low risk (15, 16).”
BackgroundParvathaneni, V., Kulkarni, N. S., Shukla, S. K., Farrales, P., Kunda, N. K., Muth, A., & Gupta, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030206 · Cited by 87
“In this milieu, drug repurposing provides an opportunity to identify a new indication for an old FDA-approved drug [13,15].”
BackgroundSelf-citationMohi-ud-din, R., Chawla, A., Sharma, P., Mir, P. A., Pottoo, F. H., Reiner, Ž., Reiner, I., Ateşşahin, D. A., Sharifi‐Rad, J., Mir, R. H., et al. (2023) · European journal of medical research · doi:10.1186/s40001-023-01275-4 · Cited by 84
“Even though polypharmacological substances are responsible for triggering undesirable side effects, their activities can be used, because they offer the possibility of additional indications for a specific drug [42].”
BackgroundRepurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
Oo, W. M., & Hunter, D. J. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221090297 · Cited by 75
Repurposing drugs in oncology: From candidate selection to clinical adoption
Pantziarka, P., Verbaanderd, C., Huys, I., Bouche, G., & Meheus, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.008 · Cited by 69
Pun, N. T., & Jeong, C. (2021) · Pharmaceuticals · doi:10.3390/ph14050470 · Cited by 75
“Drug repurposing approaches are achieved either experimentally or through a computational method by identification of drugs with new indications, new targets, new effects, and unexplored mechanisms [20].”
BackgroundInhalable bedaquiline-loaded cubosomes for the treatment of non-small cell lung cancer (NSCLC)
Patil, S. M., Sawant, S. S., & Kunda, N. K. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121046 · Cited by 70
A review for cell-based screening methods in drug discovery
Wei, F., Sicen, W., & Gou, X. (2021) · Biophysics Reports · doi:10.52601/bpr.2021.210042 · Cited by 67
“However, it remains a high failure rate in drug discovery, which causes the tendency to discover new targets for drug repurposing for more diseases (Moridani and Harirforoosh 2014; Parvathaneni et al. 2019; Wang 2018).”
BackgroundThe Art of Finding the Right Drug Target: Emerging Methods and Strategies
Jia, Z.-C., Yang, X., Wu, Y., Li, M., Das, D., Chen, M., & Wu, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001028 · Cited by 73
Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas‐Melo, F. (2025) · Pharmaceuticals · doi:10.3390/ph18060788 · Cited by 75
“This approach was historically centered on single-target drug development, but modern strategies have since evolved to enhance efficiency [24,25].”
Drug repurposing: An effective strategy to accelerate contemporary drug discovery
Zhan, P., Yu, B., & Ouyang, L. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.05.026 · Cited by 65
Drug repurposing using real-world data
Tan, G. S. Q., Sloan, E. K., Lambert, P., Kirkpatrick, C. M. J., & Ilomäki, J. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103422 · Cited by 63
Repurposing Artemisinin and its Derivatives as Anticancer Drugs: A Chance or Challenge?
Ma, Z., Woon, C. Y.-N., Liu, C., Cheng, J.-T., You, M., Sethi, G., Wong, A. L., Ho, P. C., Zhang, D., Ong, P.-S., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.828856 · Cited by 63
“, 2019), greatly reducing the cost and increasing the patients’ access to the treatment (Parvathaneni et al., 2019).”
BackgroundBousquet, J. J., Antó, J. M., Sousa‐Pinto, B., Czarlewski, W., Bedbrook, A., Haahtela, T., Klimek, L., Pfaar, O., Kuna, P., Kupczyk, M., et al. (2023) · Clinical and Translational Allergy · doi:10.1002/clt2.12215 · Cited by 63
Cui, C., Ding, X., Wang, D., Chen, L., Xiao, F., Xu, T., Zheng, M., Luo, X., Jiang, H., & Chen, K. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab191 · Cited by 58
Sun, T., Zhen, T., Harakandi, C. H., Wang, L., Guo, H., Chen, Y., & Sun, H. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116569 · Cited by 56
A Comprehensive Review of Drug Repurposing Strategies against Known Drug Targets of COVID-19
Khataniar, A., Pathak, U., Rajkhowa, S., & Jha, A. N. (2022) · COVID · doi:10.3390/covid2020011 · Cited by 56
Diuretics: a contemporary pharmacological classification?
Kehrenberg, M. C. A., & Bachmann, H. S. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02228-0 · Cited by 53
“, rare diseases or cancer with lower clinical risks and lower costs (Parvathaneni et al. 2019; Sleire et al. 2017; Talevi 2021).”
BackgroundDrug repurposing—an emerging strategy in cancer therapeutics
Turabi, K. S., Deshmukh, A. J., Paul, S., Swami, D., Siddiqui, S., Kumar, U., Naikar, S., Devarajan, S., Basu, S., Paul, M. K., et al. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02263-x · Cited by 53
“Traditional drug development is time-consuming, as it would take 10–15 years for the new drug to come into the market (Parvathaneni et al. 2019).”
BackgroundRácz, B., & Spengler, G. (2023) · Antibiotics · doi:10.3390/antibiotics12010137 · Cited by 55
“The approach has to face several challenges, including the lack of knowledge on regulatory requirements, financial and resource difficulties, new problems in clinical trials resulting in missing or inadequate proof, intellectual property issues that can hamper the commercialization of the given drug, and market analys…”
BackgroundArtificial intelligence for drug repurposing against infectious diseases
Singh, A. (2024) · Artificial Intelligence Chemistry · doi:10.1016/j.aichem.2024.100071 · Cited by 60
Drug Repurposing: Considerations to Surpass While Re-directing Old Compounds for New Treatments
Juárez-López, D., & Schcolnik‐Cabrera, A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.10.021 · Cited by 51
Artificial intelligence for life sciences: A comprehensive guide and future trends
Luo, M., Yang, W., Bai, L., Zhang, L., Huang, J., Cao, Y.-H., Xie, Y., Tong, L., Zhang, H., Lei, Y., et al. (2024) · The Innovation Life · doi:10.59717/j.xinn-life.2024.100105 · Cited by 51
Drug Repurposing: A Strategy for Discovering Inhibitors against Emerging Viral Infections
Nascimento, I. J. D. S., de Aquino, T. M., & da Silva‐Júnior, E. F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200812215852 · Cited by 62
Effective drugs used to combat SARS-CoV-2 infection and the current status of vaccines
Awadasseid, A., Wu, Y., Tanaka, Y., & Zhang, W. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111330 · Cited by 50
“assessment, and pharmacokinetic studies of FDA-approved drugs [120, 121].”
Parvathaneni, V., Kulkarni, N. S., Chauhan, G., Shukla, S. K., Elbatanony, R. S., Patel, B., Kunda, N. K., Muth, A., & Gupta, V. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111139 · Cited by 48
Self-citationPerspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
Wu, C., Hsiao, S.-H., & Wu, Y. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101011 · Cited by 47
Bousquet, J., Toumi, M., Sousa‐Pinto, B., Antó, J. M., Bedbrook, A., Czarlewski, W., Valiulis, A., Ansotegui, I. J., Bosnic-Anticevich, S. Z., Brussino, L., et al. (2022) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2022.07.020 · Cited by 56
Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer
Xu, Y., Deng, L., Diao, X., Yang, S., Zou, L., Yang, Q., Li, J., Nie, J., Zhao, L., & Jiao, B. (2023) · iScience · doi:10.1016/j.isci.2023.108218 · Cited by 46
“30 Hence, drug repurposing for TNBC treatment is a promising strategy.”
BackgroundRepurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp
Hijazi, M. A., Gessner, A., & El‐Najjar, N. (2023) · Cancers · doi:10.3390/cancers15123199 · Cited by 44
Deka, P., Gogoi, D., Althubeiti, K., Rao, D. R., & Thakuria, R. (2021) · Crystal Growth & Design · doi:10.1021/acs.cgd.1c00339 · Cited by 42
Franco‐Trepat, E., Alonso‐Pérez, A., Guillán‐Fresco, M., Mora, A. J., Crespo-Golmar, A., López‐Fagúndez, M., Pazos‐Pérez, A., Gualillo, O., Bravo, S. B., & Gómez, R. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15707 · Cited by 42
“Therefore, the search for new properties in currently approved safe drugs is a cost-effective and time-saving strategy (Parvathaneni et al., 2019).”
BackgroundNassar, H., Sippl, W., Abu‐Dahab, R., & Taha, M. O. (2023) · RSC Advances · doi:10.1039/d3ra01145c · Cited by 41
“49 Accord-ingly, third-generation cephalosporin antibiotics are introduced herein to have the structural features required for GSK3 b inhibition.”
Wadan, A.-H. S., El‐Aziz, M. K. A., & Ellakwa, D. E. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04155-2 · Cited by 51
“The long-term effects of introducing GMMs into the human body remain unclear, necessitating continuous research and transparent communication with the public to monitor their implications (Parvathaneni et al. 2019b).”
Repurposed anti-cancer drugs: the future for anti-infective therapy?
Quezada, H., Martínez‐Vázquez, M., López-Jácome, L. E., González‐Pedrajo, B., Andrade, Á., Fernández-Presas, A. M., Tovar-García, A., & García‐Contreras, R. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1752665 · Cited by 44
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Parvathaneni, V., Shukla, S. K., & Gupta, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031001 · Cited by 39
“As the discovery or development of new drugs may take exorbitantly long times, drug repurposing has become an attractive strategy to discover new uses of old FDA-approved drugs [6].”
BackgroundSelf-citationReconciling multiple connectivity scores for drug repurposing
Samart, K., Tuyishime, P., Krishnan, A., & Ravi, J. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab161 · Cited by 42
“Connectivity-based drug repurposing has been used to discover drugs in various cancers and non-cancer diseases [5].”
BackgroundAlandijany, T. A., El-Daly, M. M., Tolah, A. M., Bajrai, L. H., Khateb, A. M., Kumar, G. S., Dubey, A., Dwivedi, V. D., & Azhar, E. I. (2023) · Scientific Reports · doi:10.1038/s41598-023-41820-z · Cited by 38
“The recent studies have proven that repurposing of FDA drugs using computational approaches has been an effective approach for drug identification for treatment of several diseases 22,23 .”
BackgroundOvercoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif, T. E., Yibirin, M., Oliveira-Gomes, D. D., Machaalani, M., Nawfal, R., Carlini, G. B., Bahmad, H. F., & Bitar, N. (2022) · Cancers · doi:10.3390/cancers14092105 · Cited by 39
“Many approaches group together into either experimental or computational models [24,35].”
BackgroundFacilitating Drug Discovery in Human Disease Models Using Insects
Matsumoto, Y. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00834 · Cited by 36
Osuna‐Ramos, J. F., Farfán-Morales, C. N., Cordero‐Rivera, C. D., Jesús‐González, L. A. D., Reyes-Ruíz, J. M., Hurtado-Monzón, A. M., Palacios-Rápalo, S. N., Jiménez-Camacho, R., Meraz‐Ríos, M. A., & del Ángel, R. M. (2023) · Viruses · doi:10.3390/v15071465 · Cited by 36
Lowes, D. J., Hevener, K. E., & Peters, B. M. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01777-19 · Cited by 36
Yasir, M., Park, J., Han, E., Park, W. S., Han, J., Kwon, Y.-S., Lee, H. J., & Chun, W. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01090 · Cited by 34
Parvathaneni, V., Elbatanony, R. S., Goyal, M., Chavan, T., Vega, N., Kolluru, S., Muth, A., Gupta, V., & Kunda, N. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094783 · Cited by 34
“To overcome this emerging challenge, repurposing of old drugs has gained much traction and has led to the identification of some promising FDA-approved drugs for lung cancer treatment [3,4].”
BackgroundSelf-citationKaushal, J., Bhatia, R., Kanchan, R., Raut, P., Mallapragada, S., Ly, Q., Batra, S., & Rachagani, S. (2021) · Cancers · doi:10.3390/cancers13133105 · Cited by 35
“This method is more economical, faster, good safety profiles, and a considerably higher probability of success at the preclinical and clinical level than canonical/traditional drug development strategy [11].”
BackgroundNanomedicine for Gene Delivery and Drug Repurposing in the Treatment of Muscular Dystrophies
Andreana, I., Repellin, M., Carton, F., Kryza, D., Briançon, S., Chazaud, B., Mounier, R., Arpicco, S., Malatesta, M., Stella, B., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020278 · Cited by 34
“Drug repurposing is an effective strategy to reuse existing licensed drugs for novel medical indication while reducing development time, costs and minimising risk of failure [112,206].”
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Machine learning to design antimicrobial combination therapies: Promises and pitfalls
Cantrell, J. M., Chung, C. H., & Chandrasekaran, S. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.04.006 · Cited by 32
Elmahboub, Y., Albash, R., Ahmed, S., & Salah, S. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03233-1 · Cited by 32
Paul, A., Anand, R., Karmakar, S. P., Rawat, S., Bairagi, N., & Chatterjee, S. (2021) · Scientific Reports · doi:10.1038/s41598-020-80561-1 · Cited by 31
Drug repurposing for stroke intervention
Ghosh, D., Sehgal, K., Sodnar, B., Bhosale, N., Sarmah, D., Datta, A., Chaudhary, A., Kalia, K., Wang, X., & Bhattacharya, P. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.003 · Cited by 32
Peng, L., Bai, Z., Liu, L., Yang, L., Liu, X., Chen, M., & Chen, X. (2024) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2024.3476120 · Cited by 32
Explainable drug repurposing via path based knowledge graph completion
Jiménez, A., Merino, M. J., Parras, J., & Zazo, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-67163-x · Cited by 30
Cotrina, E. Y., Santos, L. M., Rivas, J., Blasi, D., Leite, J. P., Liz, M. A., Busquets, M. A., Planas, A., Prohens, R., Gimeno, A., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113847 · Cited by 30
Drug Repurposing for the Management of Depression: Where Do We Stand Currently?
Sadeghi, H. M., Adeli, I., Mousavi, T., Daniali, M., Nikfar, S., & Abdollahi, M. R. (2021) · Life · doi:10.3390/life11080774 · Cited by 29
“Phenotypic screening Identifying compounds showing disease consequences related effects in model systems, without any prior information about targets Pros: testing many medications for a therapeutic effect over a complete range of concentration [34], high flexibility for administration to numerous drugs or diseases [3…”
BackgroundHeterogeneous Graph Attention Network for Drug-Target Interaction Prediction
Li, M., Cai, X., Li, L., Xu, S., & Ji, H. (2022) · ACM International Conference on Information and Knowledge Management (CIKM) · doi:10.1145/3511808.3557346 · Cited by 28
“Benefiting from the rapid development of biological and chemical technologies, predicting potential DTIs from heterogeneous biological data using machine learning (ML) based methods has become the promising strategy [6, 30, 35, 38].”
BackgroundPardhi, E. R., Tomar, D. S., Khemchandani, R., Srivastava, V., Pawar, A., Yadav, R., Goud, D., Godugu, C., Samanthula, G., & Mehra, N. K. (2025) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2025.127225 · Cited by 27
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 33
Pathak, Y., Mishra, A., Choudhir, G., Kumar, A., & Tripathi, V. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00228-0 · Cited by 27
Alotaibi, G., & Alkhammash, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177509 · Cited by 26
Parvathaneni, V., Shukla, S. K., Kulkarni, N. S., & Gupta, V. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121038 · Cited by 26
Self-citationSun, J., Xu, M., Ru, J., James-Bott, A., Xiong, D., Wang, X., & Cribbs, A. P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115500 · Cited by 27
Innovative drug delivery strategies to the CNS for the treatment of multiple sclerosis
Mwema, A., Muccioli, G. G., & Rieux, A. D. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.052 · Cited by 27
Yu, W., Wang, Z., Dai, P., Sun, J., Li, J., Han, W., & Li, K. (2023) · Journal of drug targeting · doi:10.1080/1061186x.2023.2265585 · Cited by 25
“Drug repurposing has recently been identified as a cost-effective approach to rapidly bringing approved drugs into clinical treatment [44].”
BackgroundAdvances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264766 · Cited by 26
“Furthermore, the long history of medicinal chemistry in small drug synthesis provides a solid background and promising opportunities to explore drug repurposing strategies, which are not available from a biological drug approach [110].”
BackgroundGauging the role and impact of drug interactions and repurposing in neurodegenerative disorders
Khatri, D. K., Kadbhane, A., Patel, M., Nene, S., Atmakuri, S., Srivastava, S., & Singh, S. B. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100022 · Cited by 24
Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns
Mslati, H., Gentile, F., Perez, C. F., & Cherkasov, A. R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00384 · Cited by 29
Repurposing old molecules for new indications: Defining pillars of success from lessons in the past
Mittal, N., & Mittal, R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174569 · Cited by 27
Identification and Development of Therapeutics for COVID-19
Rando, H. M., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., Byrd, J. B., Rafizadeh, D. N., Qi, Y., Sun, Y., et al. (2021) · Lund University Publications (Lund University) · Cited by 26
Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC)
Parvathaneni, V., Goyal, M., Kulkarni, N. S., Shukla, S. K., & Gupta, V. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02848-2 · Cited by 25
“FDA approved molecules and hence accelerate the development process at lower costs (2).”
BackgroundSelf-citationA comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects
Bai, Y., Seng, D., Xu, Y. C., Zhang, Y., Zhou, W., Jia, Y.-Y., Song, J. Z., He, Z., Liu, H., & Yuan, S. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116706 · Cited by 24
Oyejide, A. J., Adekunle, Y. A., Abodunrin, O. D., & Atoyebi, E. O. (2025) · Intelligent Pharmacy · doi:10.1016/j.ipha.2025.01.001 · Cited by 29
Reprogramming of antibiotics to combat antimicrobial resistance
Dubey, K. K., Indu, & Sharma, M. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000168 · Cited by 24
β-lactam antibiotics to tame down molecular pathways of Alzheimer's disease
Kumari, S., & Deshmukh, R. R. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173877 · Cited by 24
DDA-SKF: Predicting Drug–Disease Associations Using Similarity Kernel Fusion
Gao, C.-Q., Zhou, Y.-K., Xin, X., Min, H., & Du, P.-F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.784171 · Cited by 24
“Today, drug repositioning has gained importance in identifying new therapeutic purposes for already-approved drugs (Parvathaneni et al., 2019).”
BackgroundDas, P., Yogita, Y., Anal, S. R. N., Pal, V., & Yadav, A. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3215645 · Cited by 24
“Empirical methods for exploring this chemical space happen to be very time consuming and costly [2], [3], [4].”
MethodGuo, X., Song, J., Liu, M., Ou, X., & Guo, Y. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2356831 · Cited by 24
“252,253 Nevertheless, implementing a high-throughput screening system for TDSEV inhibitors, coupled with quantitative assays to simultaneously assess multiple candidate inhibitors, might enhance effectiveness.”
BackgroundRepurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
Ramachandran, S., & Srivastava, S. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.08.019 · Cited by 23
“Drug repurposing has the potential to surpass several challenges associated with de novo drug discovery and guarantees quick clinical trials due to the already-established pharmacokinetics, tolerability, safety, and toxicity profile of the drug.(5) Antipsychotic drugs such as pimozide, penfluridol, fluspirilene, halop…”
BackgroundYamashita, T., Kamikaseda, S., Tanaka, A., Tozaki‐Saitoh, H., Caaveiro, J. M. M., Inoue, K., & Tsuda, M. (2021) · Cells · doi:10.3390/cells10020434 · Cited by 23
“Indeed, recent studies have pointed to new unexpected pharmacological effects of approved drugs and have provided potential insights into their eventual repurposing [20].”
BackgroundTan, X., He, Y., Huang, Y., Zheng, C., Li, J., Liu, Q., He, M., Li, B., & Xu, W. (2021) · MedComm · doi:10.1002/mco2.83 · Cited by 23
Oromucosal products – Market landscape and innovative technologies: A review
Bastos, F., Pinto, A. C., Nunes, A., & Simões, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.05.053 · Cited by 23
Dipeptidyl peptidase 4(DPP4) inhibitors stride up the management of Parkinson's disease
Maanvi, Kumari, S., & Deshmukh, R. R. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175426 · Cited by 23
Vaz, E. S., Vassiliades, S. V., Giarolla, J., Polli, M. C., & Parise‐Filho, R. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03486-4 · Cited by 24
The Current Challenges for Drug Discovery in CNS Remyelination
Balestri, S., Giovane, A. D., Sposato, C., Ferrarelli, M., & Ragnini‐Wilson, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062891 · Cited by 23
Editorial: Novel Small-Molecule Agents in Overcoming Multidrug Resistance in Cancers
Cui, Q., Wang, C., Zeng, L., Zhou, Q., & Fan, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.921985 · Cited by 23
Eltabeeb, M. A., Abdellatif, M. M., El-Nabarawi, M. A., Teaima, M. H. M., Hamed, M. I. A., Darwish, K. M., Hassan, M., Hamdan, A. M., & Hamed, R. R. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2359364 · Cited by 23
Wei, S., Sasi, C., Piepenbrock, J., Huynen, M. A., & Hoen, P. A. C. ’. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110873 · Cited by 26
Repurposing of Medicines in the EU: Launch of a Pilot Framework
Asker-Hagelberg, C., Boráň, T., Bouygues, C., Eskola, S. M., Helmle, L., Hernández, C., Houÿez, F., Lee, H., Lingri, D., Louette, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.817663 · Cited by 22
Elzahhar, P. A., Nematalla, H. A., Al-Koussa, H., Abrahamian, C., El-Yazbi, A. F., Bodgi, L., Bou-Gharios, J., Azzi, J., Al-Choboq, J., Labib, H. F., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01408 · Cited by 22
Drug Repositioning Using Computer-aided Drug Design (CADD)
Rawat, S., Subramaniam, K., Subramanian, S. K., Saravanan, S., Dhanabalan, S., Chidambaram, S. K. M., Stalin, B., Roy, A., Nagaprasad, N., Aruna, M., et al. (2023) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201024666230821103601 · Cited by 22
Martins, M., Veiga, F., Paiva‐Santos, A. C., & Pires, P. C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00679 · Cited by 23
Metadata
- Authors
- Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V.
- Affiliations
- St. John's University (US)
- Corresponding author
- Gupta, Vivek
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 24
- Issue
- 10
- Pages
- 2076-2085
- ISSN
- 1359-6446 (ISSN-L)
- PMC
- PMC11920972
- OpenAlex
- W2951512731
- Semantic Scholar
- 023e169dfa4fe591ef24cf91b93e0d7371bb3400
- Cited by
- 597
- References
- 87
- Citations by year
- 2026: 80 · 2025: 137 · 2024: 130 · 2023: 96 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 3
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Drug Discovery Today (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Figshare (submittedVersion, cc-by)
- Health Research Alliance (cc-by)
- Funders
- NIH (1R15HL138606-01A1)
- American Heart Association (18AIREA33960072)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, FDA-approved drugs, new therapeutic indications, serendipitous drug discovery, drug development challenges
- MeSH terms
- Humans, Drug Discovery, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
